Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and A β Accumulation

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Jazvinšćak Jembrek, Maja ^a,b   Hof, Patrick R ^c   Šimić, Goran ^d  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b Croatian Academy of Medical Sciences Zagreb   (Croatia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CERAMIDES; CHEMICAL ACTIVATION; DEPOSITS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYMES; FEEDBACK; NEURONS; PHOSPHOLIPIDS; PROTEINS; SIGNAL TRANSDUCTION;

EXTRACELLULAR DEPOSITS; INTRACELLULAR SIGNALLING; LIPID SECOND MESSENGER; MITOGEN ACTIVATED PROTEIN KINASE; NEURODEGENERATIVE DISORDERS; POSITIVE FEEDBACK LOOP; REACTIVE OXYGEN SPECIES; SPHINGOLIPID METABOLISM;

NEURODEGENERATIVE DISEASES;

AMYLOID BETA PROTEIN; CERAMIDE; PROTEIN; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; APOPTOSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROGLIA; NERVE CELL CULTURE; NERVE CELL DEGENERATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SPHINGOLIPID METABOLISM; ANIMAL; METABOLISM; NERVE CELL; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; CERAMIDES; HUMANS; NEURONS; OXIDATIVE STRESS;

EID: 84935870373     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/346783     Document Type: Review

References (197)

1. T.-B. Robins Wahlin and G. J. Byrne, "Personality changes in Alzheimers disease: a systematic review, " International Journal of Geriatric Psychiatry, vol. 26, no. 10, pp. 1019-1029, 2011.
2. A. Sona, K. A. Ellis, and D. Ames, "Rapid cognitive decline in Alzheimers disease: a literature review, " International Review of Psychiatry, vol. 25, no. 6, pp. 650-658, 2013.
3. R. W. Levenson, V. E. Sturm, and C. M. Haase, "Emotional and behavioral symptoms in neurodegenerative disease: a model for studying the neural bases of psychopathology, " Annual Review of Clinical Psychology, vol. 10, pp. 581-606, 2014.
4. D. P. Hanger, B. H. Anderton, and W. Noble, "Tau phosphorylation: the therapeutic challenge for neurodegenerative disease, " Trends in Molecular Medicine, vol. 15, no. 3, pp. 112-119, 2009.
5. G. Simic, M. Gnjidic, and I. Kostovic, "Cytoskeletal changes as an alternative view on pathogenesis of Alzheimers disease, " Periodicum Biologorum, vol. 100, no. 2, pp. 165-173, 1998.
6. K. Blennow, M. J. de Leon, and H. Zetterberg, "Alzheimers disease, " The Lancet, vol. 368, no. 9533, pp. 387-403, 2006.
7. G. K. Gouras, D. Tampellini, R. H. Takahashi, and E. Capetillo-Zarate, "Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimers disease, " Acta Neuropathologica, vol. 119, no. 5, pp. 523-541, 2010.
8. K. S. Vetrivel, H. Cheng, S.-H. Kim, et al., "Spatial segregation of β-secretase and substrates in distinct membrane domains, " The Journal of Biological Chemistry, vol. 280, no. 27, pp. 25892-25900, 2005.
9. G. Thinakaran and E. H. Koo, "Amyloid precursor protein trafficking, processing, and function, " Journal of Biological Chemistry, vol. 283, no. 44, pp. 29615-29619, 2008.
10. N. M. Hooper and J. V. Rushworth, "Lipid rafts: linking Alzheimers amyloid-β production, aggregation, and toxicity at neuronal membranes, " International Journal of Alzheimers Disease, vol. 2011, Article ID 603052, 14 pages, 2011.
11. M. E. Larson and S. E. Lesne, "Soluble Aβ oligomer production and toxicity, " Journal of Neurochemistry, vol. 120, supplement 1, pp. 125-139, 2012.
12. F. Hefti, W. F. Goure, J. Jerecic, K. S. Iverson, P. A. Walicke, and G. A. Krafft, "The case for soluble Aβ oligomers as a drug target in Alzheimers disease, " Trends in Pharmacological Sciences, vol. 34, no. 5, pp. 261-266, 2013.
13. J. Walter and G. van Echten-Deckert, "Cross-talk ofmembranelipids and Alzheimer-related proteins, " Molecular Neurodegeneration, vol. 8, article 34, 2013.
14. I. Ferrer, "Altered mitochondria, energy metabolism, voltagedependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimers disease, " Journal of Bioenergetics and Biomembranes, vol. 41, no. 5, pp. 425-431, 2009.
15. M. Diaz, N. Fabelo, I. Ferrer, T. Gomez, and R. Marin, "Biophysical alterations in lipid rafts from human cerebral cortex associate with increased BACE1/AβPP interaction in early stages of Alzheimers disease, " Journal of Alzheimers Disease, vol. 43, no. 4, pp. 1185-1198, 2015.
16. N. Fabelo, V. Martin, R. Marin, D. Moreno, I. Ferrer, and M. Diaz, "Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimers disease and facilitates APP/BACE1 interactions, " Neurobiology of Aging, vol. 35, no. 8, pp. 1801-1812, 2014.
17. R. S. Yadav and N. K. Tiwari, "Lipid integration in neurodegeneration: an overview of Alzheimers disease, " Molecular Neurobiology, vol. 50, no. 1, pp. 168-176, 2014.
18. L. Bertram, C. M. Lill, and R. E. Tanzi, "The genetics of alzheimer disease: back to the future, " Neuron, vol. 68, no. 2, pp. 270-281, 2010.
19. C.-C. Liu, T. Kanekiyo, H. Xu, and G. Bu, "Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy, " Nature Reviews Neurology, vol. 9, no. 2, pp. 106-118, 2013.
20. V. Solfrizzi, A. DIntrono, A. M. Colacicco, et al., "Dietary fatty acids intake: possible role in cognitive decline and dementia, " Experimental Gerontology, vol. 40, no. 4, pp. 257-270, 2005.
21. R. Takechi, S. Galloway, M. M. S. Pallebage-Gamarallage, V. Lam, and J. C. L. Mamo, "Dietary fats, cerebrovasculature integrity and Alzheimers disease risk, " Progress in Lipid Research, vol. 49, no. 2, pp. 159-170, 2010.
22. M. C. Morris and C. C. Tangney, "Dietary fat composition and dementia risk, " Neurobiology of Aging, vol. 35, supplement 2, pp. S59-S64, 2014.
23. C. D. Morrison, P. J. Pistell, D. K. Ingram, et al., "High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling, " Journal of Neurochemistry, vol. 114, no. 6, pp. 1581-1589, 2010.
24. A. M. Stranahan, R. G. Cutler, C. Button, R. Telljohann, and M. P. Mattson, "Diet-induced elevations in serum cholesterol are associatedwith alterations in hippocampal lipidmetabolism and increased oxidative stress, " Journal of Neurochemistry, vol. 118, no. 4, pp. 611-615, 2011.
25. X. He, Y. Huang, B. Li, C.-X. Gong, and E. H. Schuchman, "Deregulation of sphingolipid metabolism in Alzheimers disease, " Neurobiology of Aging, vol. 31, no. 3, pp. 398-408, 2010.
26. M. B. Dinkins, S. Dasgupta, G. Wang, et al., "The 5XFAD mouse model of Alzheimer's disease exhibits an age-dependent increase in anti-ceramide IgG and exogenous administration of ceramide further increases anti-ceramide titers and amyloid plaque burden, " Journal of Alzheimers Disease, vol. 46, no. 1, 2015.
27. R. G. Cutler, J. Kelly, K. Storie, et al., "Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimers disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2070-2075, 2004.
28. K. Fassbender, M. Simons, C. Bergmann, et al., "Simvastatin strongly reduces levels of Alzheimers disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5856-5861, 2001.
29. I. Y. Tamboli, K. Prager, E. Barth, M. Heneka, K. Sand hoff, and J. Walter, "Inhibition of glycosphingolipid biosynthesis reduces secretion of the β-amyloid precursor protein and amyloid β-peptide, " The Journal of Biological Chemistry, vol. 280, no. 30, pp. 28110-28117, 2005.
30. A. Jana, E. L. Hogan, and K. Pahan, "Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death, " Journal of the Neurological Sciences, vol. 278, no. 1-2, pp. 5-15, 2009.
31. N. E. Shepardson, G. M. Shankar, and D. J. Selkoe, "Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations, " Archives of Neurology, vol. 68, no. 11, pp. 1385-1392, 2011.
32. M. B. Dinkins, S. Dasgupta, G. Wang, G. Zhu, and E. Bieberich, "Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFADmousemodel of Alzheimers disease, " Neurobiology of Aging, vol. 35, no. 8, pp. 1792-1800, 2014.
33. G. Simic, I. Kostovic, B. Winblad, and N. Bogdanovic, "Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimers disease, " The Journal of Comparative Neurology, vol. 379, no. 4, pp. 482-494, 1997.
34. J. H. Morrison and P. R. Hof, "Life and death of neurons in the aging brain, " Science, vol. 278, no. 5337, pp. 412-419, 1997.
35. D. G. Smith, R. Cappai, and K. J. Barnham, "The redox chemistry of the Alzheimers disease amyloid β peptide, " Biochimicaet Biophysica Acta, vol. 1768, no. 8, pp. 1976-1990, 2007.
36. P. H. Axelsen, H. Komatsu, and I. V. J. Murray, "Oxidative stress and cellmembranes in the pathogenesis of Alzheimers disease, " Physiology, vol. 26, no. 1, pp. 54-69, 2011.
37. P. Carrillo-Mora, R. Luna, and L. Colin-Barenque, "Amyloid beta: multiple mechanisms of toxicity and only some protective effects?" Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 795375, 15 pages, 2014.
38. D. J. Bonda, X. Wang, G. Perry, et al., "Oxidative stress in Alzheimer disease: a possibility for prevention, " Neuropharmacology, vol. 59, no. 4-5, pp. 290-294, 2010.
39. R. M. Uranga, A. J. Bruce-Keller, C. D. Morrisonet al., "Intersection betweenmetabolic dysfunction, high fat diet consumption, and brain aging, " Journal of Neurochemistry, vol. 114, no. 2, pp. 344-361, 2010.
40. M. Maceyka, S. Milstien, and S. Spiegel, "Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling, " Journal of Lipid Research, vol. 50, supplement, pp. S272-S276, 2009.
41. H. Hering, C.-C. Lin, and M. Sheng, "Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability, " The Journal of Neuroscience, vol. 23, no. 8, pp. 3262-3271, 2003.
42. S. A. Young, J. G. Mina, P. W. Denny, and T. K. Smith, "Sphingolipid and ceramide homeostasis: potential therapeutic targets, " Biochemistry Research International, vol. 2012, Article ID 248135, 12 pages, 2012.
43. C. Mencarelli and P. Martinez-Martinez, "Ceramide function in the brain: when a slight tilt is enough, " Cellular and Molecular Life Sciences, vol. 70, no. 2, pp. 181-203, 2013.
44. N. J. Haughey, V. V. R. Band aru, M. Bae, and M. P. Mattson, "Roles for dysfunctional sphingolipid metabolism in Alzheimers disease neuropathogenesis, " Biochimicaet Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1801, no. 8, pp. 878-886, 2010.
45. M. M. Mielke and C. G. Lyketsos, "Alterations of the sphingolipid pathway in Alzheimers disease: new biomarkers and treatment targets?" NeuroMolecular Medicine, vol. 12, no. 4, pp. 331-340, 2010.
46. R. P. Rao, N. Vaidyanathan, M. Rengasamy, A. M. Oommen, N. Somaiya, and M. R. Jagannath, "Sphingolipid metabolic pathway: an overview of major roles played in human diseases, " Journal of Lipids, vol. 2013, Article ID 178910, 12 pages, 2013.
47. M. Kosicek, H. Zetterberg, N. Andreasen, J. Peter-Katalinic, and S. Hecimovic, "Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimers disease, " Neuroscience Letters, vol. 516, no. 2, pp. 302-305, 2012.
48. M. M. Mielke, N. J. Haughey, V. V. R. Band aru, et al., "Plasma sphingomyelins are associated with cognitive progression in alzheimers disease, " Journal of Alzheimers Disease, vol. 27, no. 2, pp. 259-269, 2011.
49. Y. A. Hannun and L. M. Obeid, "Principles of bioactive lipid signalling: lessons from sphingolipids, " Nature Reviews. Molecular Cell Biology, vol. 9, no. 2, pp. 139-150, 2008.
50. O. Ben-David and A. H. Futerman, "The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases, " NeuroMolecular Medicine, vol. 12, no. 4, pp. 341-350, 2010.
51. J. Rohrbough, E. Rushton, L. Palanker, et al., "Ceramidase regulates synaptic vesicle exocytosis and trafficking, " The Journal of Neuroscience, vol. 24, no. 36, pp. 7789-7803, 2004.
52. N. Marchesini and Y. A. Hannun, "Acid and neutral sphingomyelinases: roles and mechanisms of regulation, " Biochemistry and Cell Biology, vol. 82, no. 1, pp. 27-44, 2004.
53. R. W. Jenkins, D. Canals, and Y. A. Hannun, "Roles and regulation of secretory and lysosomal acid sphingomyelinase, " Cellular Signalling, vol. 21, no. 6, pp. 836-846, 2009.
54. M. Kronke, "Involvement of sphingomyelinases in TNF signaling pathways, " Chemistry and Physics of Lipids, vol. 102, no. 1-2, pp. 157-166, 1999.
55. S. A. Novgorodov and T. I. Gudz, "Ceramide and mitochondria in ischemic brain injury, " International Journal of Biochemistry and Molecular Biology, vol. 2, no. 4, pp. 347-361, 2011.
56. M. M. Mielke, V. V. R. Band aru, N. J. Haughey, et al., "Serum ceramides increase the risk of Alzheimer disease: the Womens Health and Aging Study II, " Neurology, vol. 79, no. 7, pp. 633-641, 2012.
57. X. Han, D. M. Holtzman, D. W. McKeel Jr., J. Kelley, and J. C. Morris, "Substantial sulfatide deficiency and ceramide elevation in very early Alzheimers disease: potential role in disease pathogenesis, " Journal of Neurochemistry, vol. 82, no. 4, pp. 809-818, 2002.
58. V. Filippov, M. A. Song, K. Zhang, et al., "Increased ceramide in brains with Alzheimers and other neurodegenerative diseases, " Journal of Alzheimers Disease, vol. 29, no. 3, pp. 537-547, 2012.
59. M. M. Mielke, V. V. R. Band aru, N. J. Haughey, P. V. Rabins, C. G. Lyketsos, and M. C. Carlson, "Serum sphingomyelins and ceramides are early predictors of memory impairment, " Neurobiology of Aging, vol. 31, no. 1, pp. 17-24, 2010.
60. C. Costantini, R. Weindruch, G. D. Valle, and L. Puglielli, "A TrkA-to-p75NTR molecular switch activates amyloid β-peptide generation during aging, " The Biochemical Journal, vol. 391, no. 1, pp. 59-67, 2005.
61. P. Katsel, C. Li, and V. Haroutunian, "Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimers disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimers disease?" Neurochemical Research, vol. 32, no. 4-5, pp. 845-856, 2007.
62. M. M. Mielke and N. J. Haughey, "Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimers disease?" Clinical Lipidology, vol. 7, no. 5, pp. 525-536, 2012.
63. R. E. Toman, V. Movsesyan, S. K. Murthy, S. Milstien, S. Spiegel, and A. I. Faden, "Ceramide-induced cell death in primary neuronal cultures: upregulation of ceramide levels during neuronal apoptosis, " Journal of Neuroscience Research, vol. 68, no. 3, pp. 323-330, 2002.
64. L. Puglielli, B. C. Ellis, A. J. Saunders, and D. M. Kovacs, "Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis, " The Journal of Biological Chemistry, vol. 278, no. 22, pp. 19777-19783, 2003.
65. C.-M. Tang, C.-S. Hwang, S.-D. Chen, and D.-I. Yang, "Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: roles of Bcl-2 and thioredoxin, " Free Radical Biology and Medicine, vol. 50, no. 6, pp. 710-721, 2011.
66. B. M. Barth, S. J. Gustafson, and T. B. Kuhn, "Neutral sphingomyelinase activation precedes NADPH oxidase-dependent damage in neurons exposed to the proinflammatory cytokine tumor necrosis factor-β, " Journal of Neuroscience Research, vol. 90, no. 1, pp. 229-242, 2012.
67. A. M. Vacaru, F. G. Tafesse, P. Ternes, et al., "Sphingomyelin synthase-related protein SMSr controls ceramide homeostasis in the ER, " The Journal of Cell Biology, vol. 185, no. 6, pp. 1013-1027, 2009.
68. O. Cuvillier, G. Pirianov, B. Kleuser, et al., "Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate, " Nature, vol. 381, no. 6585, pp. 800-803, 1996.
69. A. Gomez-Brouchet, D. Pchejetski, L. Brizuela, et al., "Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide, " Molecular Pharmacology, vol. 72, no. 2, pp. 341-349, 2007.
70. K. Czubowicz and R. Strosznajder, "Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate, " Molecular Neurobiology, vol. 50, no. 1, pp. 26-37, 2014.
71. S. Rosales-Corral, D. Acuna-Castroviejo, D. X. Tan, et al., "Accumulation of exogenous amyloid-β peptide in hippocampal mitochondria causes their dysfunction: a protective role for melatonin, " Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID843649, 15 pages, 2012.
72. S. Chakrabarti, M. Sinha, I. G. Thakurta, P. Banerjee, and M. Chattopadhyay, "Oxidative stress and amyloid beta toxicity in Alzheimers disease: intervention in a complex relationship by antioxidants, " Current Medicinal Chemistry, vol. 20, no. 37, pp. 4648-4664, 2013.
73. V. France-Lanord, B. Brugg, P. P. Michel, Y. Agid, and M. Ruberg, "Mitochondrial free radical signal in ceramidedependent apoptosis: a putative mechanism for neuronal death in Parkinsons disease, " Journal of Neurochemistry, vol. 69, no. 4, pp. 1612-1621, 1997.
74. N. Lambeng, P. P. Michel, B. Brugg, Y. Agid, and M. Ruberg, "Mechanisms of apoptosis in PC12 cells irreversibly differentiated with nerve growth factor and cyclic AMP, " Brain Research, vol. 821, no. 1, pp. 60-68, 1999.
75. F. Darios, N. Lambeng, J.-D. Troadec, P. P. Michel, and M. Ruberg, "Ceramide increases mitochondrial free calcium levels via caspase 8 and Bid: role in initiation of cell death, " Journal of Neurochemistry, vol. 84, no. 4, pp. 643-654, 2003.
76. V. V. T. S. Prasad, K. Nithipatikom, and D. R. Harder, "Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes, " Neurochemistry International, vol. 53, no. 68, pp. 220229, 2008.
77. D. A. Butterfield, A. M. Swomley, and R. Sultana, "Amyloid β-Peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression, " Antioxidants & Redox Signaling, vol. 19, no. 8, pp. 823-835, 2013.
78. M. Pohanka, "Alzheimers disease and oxidative stress: a review, " Current Medicinal Chemistry, vol. 21, no. 3, pp. 356-364, 2014.
79. Y. Zhao and B. Zhao, "Oxidative stress and the pathogenesis of Alzheimers disease, " OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID 316523, 10 pages, 2013.
80. J. Emerit, M. Edeas, and F. Bricaire, "Neurodegenerative diseases and oxidative stress, " Biomedicine and Pharmacotherapy, vol. 58, no. 1, pp. 39-46, 2004.
81. J. E. Slemmer, J. J. Shacka, M. I. Sweeney, and J. T. Weber, "Antioxidants and free radical seavengers for the treatment of stroke, traumatic brain injury and aging, " Current Medicinal Chemistry, vol. 15, no. 4, pp. 404-414, 2008.
82. M. L. Circu and T. Y. Aw, "Reactive oxygen species, cellular redox systems, and apoptosis, " Free Radical Biology and Medicine, vol. 48, no. 6, pp. 749-762, 2010.
83. B. Uttara, A. V. Singh, P. Zamboni, and R. T. Mahajan, "Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options, " Current Neuropharmacology, vol. 7, no. 1, pp. 65-74, 2009.
84. F. Gueraud, M. Atalay, N. Bresgen, et al., "Chemistry and biochemistry of lipid peroxidation products, " Free Radical Research, vol. 44, no. 10, pp. 1098-1124, 2010.
85. S. Dalleau, M. Baradat, F. Gueraud, and L. Huc, "Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance, " Cell Death & Differentiation, vol. 20, no. 12, pp. 1615-1630, 2013.
86. M. Shoeb, N. H. Ansari, S. K. Srivastava, and K. V. Ramana, "4-hydroxynonenal in the pathogenesis and progression of human diseases, " Current Medicinal Chemistry, vol. 21, no. 2, pp. 230-237, 2014.
87. R. Sultana, M. Perluigi, and D. A. Butterfield, "Lipid peroxidation triggers neurodegeneration: a redox proteomics view into theAlzheimer disease brain, "FreeRadical Biology and Medicine, vol. 62, pp. 157-169, 2013.
88. N. Papaioannou, P. C. J. Tooten, A. M. van Ederen, et al., "Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques, " Amyloid, vol. 8, no. 1, pp. 11-21, 2001.
89. H. F. Poon, V. Calabrese, G. Scapagnini, and D. A. Butterfield, "Free radicals and brain aging, " Clinics in Geriatric Medicine, vol. 20, no. 2, pp. 329-359, 2004.
90. W. R. Markesbery and J. M. Carney, "Oxidative alterations in Alzheimers disease, " Brain Pathology, vol. 9, no. 1, pp. 133-146, 1999.
91. M. C. Morris, D. A. Evans, J. L. Bienias, et al., "Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease, " Archives of Neurology, vol. 60, no. 7, pp. 940-946, 2003.
92. Y. Gu, N. Schupf, S. A. Cosentino, J. A. Luchsinger, and N. Scarmeas, "Nutrient intake and plasma β-amyloid, " Neurology, vol. 78, no. 23, pp. 1832-1840, 2012.
93. G. P. Lim, F. Calon, T. Morihara, et al., "A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model, " Journal of Neuroscience, vol. 25, no. 12, pp. 3032-3040, 2005.
94. D. Arsenault, C. Julien, C. Tremblay, and F. Calon, "DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice, " PLoS ONE, vol. 6, no. 2, Article ID e17397, 2011.
95. R. J. Mark, Z. Pang, J. W. Geddes, K. Uchida, and M. P. Mattson, "Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation, " The Journal of Neuroscience, vol. 17, no. 3, pp. 1046-1054, 1997.
96. C.-X. Gong, F. Liu, I. Grundke-Iqbal, and K. Iqbal, "Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation, " Journal of Alzheimers Disease, vol. 9, no. 1, pp. 1-12, 2006.
97. R. O. Kuljis and M. Salkovic-Petrisic, "Dementia, diabetes, Alzheimers disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics, " Journal of Alzheimers Disease, vol. 25, no. 1, pp. 29-41, 2011.
98. Z. Chen and C. Zhong, "Decoding Alzheimers disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies, " Progress in Neurobiology, vol. 108, pp. 21-43, 2013.
99. D. Luque-Contreras, K. Carvajal, D. Toral-Rios, D. Franco-Bocanegra, and V. Campos-Pena, "Oxidative stress and metabolic syndrome: cause or consequence of Alzheimers disease?" Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 497802, 11 pages, 2014.
100. M. A. Lovell, C. Xie, S. P. Gabbita, and W. R. Markesbery, "Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimers disease brain, " Free Radical Biology and Medicine, vol. 28, no. 3, pp. 418-427, 2000.
101. M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell, and W. R. Markesbery, "Copper, iron and zinc in Alzheimers disease senile plaques, " Journal of the Neurological Sciences, vol. 158, no. 1, pp. 47-52, 1998.
102. N. Arnal, D. O. Cristalli, M. J. T. de Alaniz, and C. A. Marra, "Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives, " Brain Research, vol. 1319, pp. 118-130, 2010.
103. A. Hordyjewska, L. Popiolek, and J. Kocot, "The many faces of copper in medicine and treatment, " BioMetals, vol. 27, no. 4, pp. 611-621, 2014.
104. L. M. Gaetke and C. K. Chow, "Copper toxicity, oxidative stress, and antioxidant nutrients, " Toxicology, vol. 189, no. 1-2, pp. 147-163, 2003.
105. M. Jazvinscak Jembrek, J. Vlainic, V. Radovanovic, J. Erhardt, and N. Orsolic, "Effects of copper overload in P19 neurons: impairment of glutathione redox homeostasis and crosstalk between caspase and calpain protease systems in ROS-induced apoptosis, " Biometals, vol. 27, no. 6, pp. 1303-1322, 2014.
106. D. L. Sparks and B. G. Schreurs, "Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimers disease, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 100, no. 19, pp. 11065-11069, 2003.
107. M. Kitazawa, D. Cheng, and F. M. Laferla, "Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD, " Journal of Neurochemistry, vol. 108, no. 6, pp. 1550-1560, 2009.
108. P. A. Lang, M. Schenck, J. P. Nicolay, et al., "Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide, " Nature Medicine, vol. 13, no. 2, pp. 164-170, 2007.
109. L. E. Lyn-Cook Jr., M. Lawton, M. Tong, et al., "Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis, " Journal of Alzheimers Disease, vol. 16, no. 4, pp. 715-729, 2009.
110. G. Olivieri, G. Baysang, F. Meier, et al., "N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on β-amyloid secretion and tau phosphorylation, " Journal of Neurochemistry, vol. 76, no. 1, pp. 224-233, 2001.
111. E. Giraldo, A. Lloret, T. Fuchsberger, and J. Vina, "Aβ and tau toxicities in Alzheimers are linked via oxidative stress-induced p38 activation: protective role of vitamin E, " Redox Biology, vol. 2, pp. 873-877, 2014.
112. G. Smale, N. R. Nichols, D. R. Brady, C. E. Finch, and W. E. Horton Jr., "Evidence for apoptotic cell death in Alzheimers disease, " Experimental Neurology, vol. 133, no. 2, pp. 225-230, 1995.
113. A. J. Anderson, S. Stoltzner, F. Lai, J. Su, and R. A. Nixon, "Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL, " Neurobiology of Aging, vol. 21, no. 4, pp. 511-524, 2000.
114. E. Engidawork, T. Gulesserian, R. Seidl, N. Cairns, and G. Lubec, "Expression of apoptosis related proteins in brains of patients with Alzheimers disease, " Neuroscience Letters, vol. 303, no. 2, pp. 79-82, 2001.
115. A. Kogot-Levin and A. Saada, "Ceramide and the mitochondrial respiratory chain, " Biochimie, vol. 100, no. 1, pp. 88-94, 2014.
116. V. A. Movsesyan, A. G. Yakovlev, E. A. Dabaghyan, B. A. Stoica, and A. I. Faden, "Ceramide induces neuronal apoptosis through the caspase-9/caspase-3 pathway, " Biochemical and Biophysical Research Communications, vol. 299, no. 2, pp. 201-207, 2002.
117. B. A. Stoica, V. A. Movsesyan, P. M. Lea IV, and A. I. Faden, "Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3β, and induction of the mitochondrial-dependent intrinsic caspase pathway, "Molecular and Cellular Neuroscience, vol. 22, no. 3, pp. 365-382, 2003.
118. T.-C. Ju, S.-D. Chen, C.-C. Liu, and D.-I. Yang, "Protective effects of S-nitrosoglutathione against amyloid β-peptide neurotoxicity, " Free Radical Biology and Medicine, vol. 38, no. 7, pp. 938-949, 2005.
119. P. Ghafourifar, S. D. Klein, O. Schucht, et al., "Ceramide induces cytochrome c release from isolated mitochondria. Importance of mitochondrial redox state, " The Journal of Biological Chemistry, vol. 274, no. 10, pp. 6080-6084, 1999.
120. L. J. Siskind, R. N. Kolesnick, and M. Colombini, "Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins, " The Journal of Biological Chemistry, vol. 277, no. 30, pp. 26796-26803, 2002.
121. M. Colombini, "Ceramide channels and their role in mitochondria-mediated apoptosis, " Biochimicaet Biophysica Acta, vol. 1797, no. 6-7, pp. 1239-1244, 2010.
122. B. A. Stoica, V. A. Movsesyan, S. M. Knoblach, and A. I. Faden, "Ceramide induces neuronal apoptosis through mitogenactivated protein kinases and causes release of multiple mitochondrial proteins, " Molecular and Cellular Neuroscience, vol. 29, no. 3, pp. 355-371, 2005.
123. M.-P. Muriel, N. Lambeng, F. Darios, et al., "Mitochondrial free calcium levels (Rhod-2 fluorescence) and ultrastructural alterations in neuronally differentiated PC12 cells during ceramidedependent cell death, " The Journal of Comparative Neurology, vol. 426, no. 2, pp. 297-315, 2000.
124. F. Darios, O. Corti, C. B. Lucking, et al., "Parkin prevents mitochondrial swelling and cytochrome c release in mitochondriadependent cell death, " HumanMolecular Genetics, vol. 12, no. 5, pp. 517-526, 2003.
125. X. Zhang, J. Wu, Y. Dou, et al., "Asiatic acid protects primary neurons against C2-ceramide-induced apoptosis, " European Journal of Pharmacology, vol. 679, no. 1-3, pp. 51-59, 2012.
126. A. Falluel-Morel, N. Aubert, D. Vaudry, et al., "Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells, " Journal of Neurochemistry, vol. 91, no. 5, pp. 1231-1243, 2004.
127. P. Li, D. Nijhawan, I. Budihardjo, et al., "Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade, " Cell, vol. 91, no. 4, pp. 479-489, 1997.
128. A. Ito, T. Uehara, A. Tokumitsu, Y. Okuma, and Y. Nomura, "Possible involvement of cytochrome c release and sequential activation of caspases in ceramide-induced apoptosis in SKN-MC cells, " Biochimicaet Biophysica Acta-Molecular Cell Research, vol. 1452, no. 3, pp. 263-274, 1999.
129. H. K. Nam, K. Kim, S. P. Weon, H. S. Son, and Y. Bae, "PKB/Akt inhibits ceramide-induced apoptosis in neuroblastoma cells by blocking apoptosis-inducing factor (AIF) translocation, " Journal of Cellular Biochemistry, vol. 102, no. 5, pp. 1160-1170, 2007.
130. H. Zhou, S. A. Summers, M. J. Birnbaum, and R. N. Pittman, "Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis, " The Journal of Biological Chemistry, vol. 273, no. 26, pp. 16568-16575, 1998.
131. C.-F. Lin, C.-L. Chen, C.-W. Chiang, M.-S. Jan, W.-C. Huang, and Y.-S. Lin, "GSK-3β acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramideinduced mitochondrial apoptosis, " Journal of Cell Science, vol. 120, no. 16, pp. 2935-2943, 2007.
132. M. Jazvinscak Jembrek, M. Babic, N. Pivac, P. R. Hof, and G. Simic, "Hyperphosphorylation of tau by GSK-3β in Alzheimers disease: the interaction of Aβ and sphingolipid mediators as a therapeutic target, " Translational Neuroscience, vol. 4, no. 4, pp. 466-476, 2013.
133. M. Salinas, R. Lopez-Valdaliso, D. Martin, A. Alvarez, and A. Cuadrado, "Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells, " Molecular and Cellular Neurosciences, vol. 15, no. 2, pp. 156-169, 2000.
134. V. Janssens and J. Goris, "Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling, " The Biochemical Journal, vol. 353, no. 3, pp. 417-439, 2001.
135. C. E. Chalfant, Z. Szulc, P. Roddy, A. Bielawska, and Y. A. Hannun, "The structural requirements for ceramide activation of serine-threonine protein phosphatases, " Journal of Lipid Research, vol. 45, no. 3, pp. 496-506, 2004.
136. Y. C. Kuo, K. Y. Huang, C. H. Yang, Y. S. Yang, W. Y. Lee, and C. W. Chiang, "Regulation of phosphorylation ofThr-308 of Akt, cell proliferation, and survival by the B55β regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt, " The Journal of Biological Chemistry, vol. 283, no. 4, pp. 1882-1892, 2008.
137. P. P. Ruvolo, X. Deng, T. Ito, B. K. Carr, and W. S. May, "Ceramide induces Bcl2 dephosphorylation via a mechanism involvingmitochondrial PP2A, "TheJournal of Biological Chemistry, vol. 274, no. 29, pp. 20296-20300, 1999.
138. R. J. Griffin, A. Moloney, M. Kelliher, et al., "Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimers disease pathology, " Journal of Neurochemistry, vol. 93, no. 1, pp. 105-117, 2005.
139. A. Ismail, K. Ning, A. Al-Hayani, B. Sharrack, and M. Azzouz, "PTEN: a molecular target for neurodegeneratIve disorders, " Translational Neuroscience, vol. 3, no. 2, pp. 132-142, 2012.
140. J. Cui, M. Zhang, Y.-Q. Zhang, and Z.-H. Xu, "JNK pathway: diseases and therapeutic potential, " Acta Pharmacologica Sinica, vol. 28, no. 5, pp. 601-608, 2007.
141. S. Soeda, Y. Tsuji, T. Ochiai, et al., "Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress, " Neurochemistry International, vol. 45, no. 5, pp. 619-626, 2004.
142. S. Willaime-Morawek, K. Brami-Cherrier, J. Mariani, J. Caboche, and B. Brugg, "c-Jun N-terminal kinases/c-Jun and p38 pathways cooperate in ceramide-induced neuronal apoptosis, " Neuroscience, vol. 119, no. 2, pp. 387-397, 2003.
143. S. Willaime, P. Vanhoutte, J. Caboche, Y. Lemaigre-Dubreuil, J. Mariani, and B. Brugg, "Ceramide-induced apoptosis in cortical neurons ismediated by an increase in p38 phosphorylation and not by the decrease in ERK phosphorylation, " The European Journal of Neuroscience, vol. 13, no. 11, pp. 2037-2046, 2001.
144. F. M. LaFerla, B. T. Tinkle, C. J. Bieberich, C. C. Haudenschild, and G. Jay, "The Alzheimers Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice, " Nature Genetics, vol. 9, no. 1, pp. 21-30, 1995.
145. E. Masliah, A. Sisk, M. Mallory, L. Mucke, D. Schenk, and D. Games, "Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F/β-amyloid precursor protein and Alzheimers disease, " The Journal of Neuroscience, vol. 16, no. 18, pp. 5795-5811, 1996.
146. W. E. G. Muller, F. J. Romero, S. Perovic, G. Pergand e, and P. Pialoglou, "Protection of flupirtine on β-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloidinduced glutathione depletion, " Journal of Neurochemistry, vol. 68, no. 6, pp. 2371-2377, 1997.
147. Y. Morishima, Y. Gotoh, J. Zieg, et al., "β-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun Nterminal kinase pathway and the induction of fas ligand, " The Journal of Neuroscience, vol. 21, no. 19, pp. 7551-7560, 2001.
148. S. Shimohama, "Apoptosis in Alzheimers disease-an update, " Apoptosis, vol. 5, no. 1, pp. 9-16, 2000.
149. T.-C. Ju, S.-D. Chen, C.-C. Liu, and D.-I. Yang, "Protective effects of S-nitrosoglutathione against amyloid β-peptide neurotoxicity, " Free Radical Biology and Medicine, vol. 38, no. 7, pp. 938-949, 2005.
150. A. Diana, G. Simic, E. Sinforiani, N. Orru, G. Pichiri, and G. Bono, "Mitochondria morphology and DNA content upon sublethal exposure to beta-amyloid1-42 peptide, " Collegium Antropologicum, vol. 32, no. 1, pp. 51-58, 2008.
151. E. Ferreiro, C. R. Oliveira, and C. M. F. Pereira, "The release of calcium from the endoplasmic reticulum induced by amyloidbeta and prion peptides activates the mitochondrial apoptotic pathway, " Neurobiology of Disease, vol. 30, no. 3, pp. 331-342, 2008.
152. M. Yao, T.-V. V. Nguyen, and C. J. Pike, "β-Amyloidinduced neuronal apoptosis involves c-Jun N-terminal kinasedependent downregulation of Bcl-w, " The Journal of Neuroscience, vol. 25, no. 5, pp. 1149-1158, 2005.
153. S. Chen, J.-M. Lee, C. Zeng, H. Chen, C. Y. Hsu, and J. Xu, "Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes, " Journal of Neurochemistry, vol. 97, no. 3, pp. 631-640, 2006.
154. Y. Xu, X.-Y. Hou, Y. Liu, and Y.-Y. Zong, "Different protection of K252a and n-acetyl-L-cysteine against amyloid-β peptideinduced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades, " Journal of Neuroscience Research, vol. 87, no. 4, pp. 918-927, 2009.
155. X.-Y. Qin, Y. Cheng, and L.-C. Yu, "Potential protection of curcumin against intracellular amyloid β-induced toxicity in cultured rat prefrontal cortical neurons, " Neuroscience Letters, vol. 480, no. 1, pp. 21-24, 2010.
156. H. Dong, S. Mao, J. Wei, et al., "Tanshinone IIA protects PC12 cells from β-amyloid 25-35-induced apoptosis via PI3K/Akt signaling pathway, "Molecular Biology Reports, vol. 39, no. 6, pp. 6495-6503, 2012.
157. S. Zhi-Kun, Y. Hong-Qi, W. Zhi-Quan, P. Jing, H. Zhen, and C. Sheng-Di, "Erythropoietin prevents PC12 cells from betaamyloid-induced apoptosis via PI3K/Akt pathway, " Translational Neurodegeneration, vol. 1, no. 1, article 7, 2012.
158. J. J. Abbott, D. R. Howlett, P. T. Francis, and R. J. Williams, "Aβ1-42 modulation of Akt phosphorylation via α7 nAChR and NMDA receptors, " Neurobiology of Aging, vol. 29, no. 7, pp. 992-1001, 2008.
159. B. Liu, D. F. Hassler, G. K. Smith, K. Weaver, and Y. A. Hannun, "Purification and characterization of a membrane bound neutral pH optimum magnesium-dependent and phosphatidylserine-stimulated sphingomyelinase from rat brain, "The Journal of Biological Chemistry, vol. 273, no. 51, pp. 34472-34479, 1998.
160. C. J. Clarke and Y. A. Hannun, "Neutral sphingomyelinases and nSMase2: bridging the gaps, " Biochimicaet Biophysica Acta, vol. 1758, no. 12, pp. 1893-1901, 2006.
161. D. Martin, M. Salinas, N. Fujita, T. Tsuruo, and A. Cuadrado, "Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B, "The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42943-42952, 2002.
162. A. Jana and K. Pahan, "Fibrillar amyloid-β peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimers disease, " The Journal of Biological Chemistry, vol. 279, no. 49, pp. 51451-51459, 2004.
163. P. P. Dotson II, A. A. Karakashian, and M. N. Nikolova-Karakashian, "Neutral sphingomyelinase-2 is a redox sensitive enzyme: role of catalytic cysteine residues in regulation of enzymatic activity through changes in oligomeric state, " The Biochemical Journal, vol. 465, no. 3, pp. 371-382, 2014.
164. M. Panchal, M. Gaudin, A. N. Lazar, et al., "Ceramides and sphingomyelinases in senile plaques, " Neurobiology of Disease, vol. 65, pp. 193-201, 2014.
165. N. A. Crivello, I. H. Rosenberg, G. E. Dallal, D. Bielinski, and J. A. Joseph, "Age-related changes in neutral sphingomyelinspecific phospholipase C activity in striatum, hippocampus, and frontal cortex: implication for sensitivity to stress and inflammation, " Neurochemistry International, vol. 47, no. 8, pp. 573-579, 2005.
166. H. Li, W. S. Kim, G. J. Guillemin, A. F. Hill, G. Evin, and B. Garner, "Modulation of amyloid precursor protein processing by synthetic ceramide analogues, " Biochimicaet Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1801, no. 8, pp. 887-895, 2010.
167. J. M. Cordy, I. Hussain, C. Dingwall, N. M. Hooper, and A. J. Turner, "Exclusively targeting β-secretase to lipid rafts by GPIanchor addition up-regulates β-site processing of the amyloid precursor protein, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11735-11740, 2003.
168. E. Takasugi, T. Sasaki, M. Shinohara, T. Iwatsubo, and T. Tomita, "Synthetic ceramide analogues increase amyloid-β 42 production bymodulating β-secretase activity, " Biochemical and Biophysical Research Communications, vol. 457, no. 2, pp. 194-199, 2015.
169. J.-T. Lee, J. Xu, J.-M. Lee, et al., "Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway, " The Journal of Cell Biology, vol. 164, no. 1, pp. 123-131, 2004.
170. M. O. W. Grimm, H. S. Grimm, A. J. Patzold, et al., "Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin, " Nature Cell Biology, vol. 7, no. 11, pp. 1118-1123, 2005.
171. C. Malaplate-Armand, S. Florent-Bechard, I. Youssef, et al., "Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway, " Neurobiology of Disease, vol. 23, no. 1, pp. 178-189, 2006.
172. A. V. Alessenko, A. E. Bugrova, and L. B. Dudnik, "Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimers disease, " Biochemical Society Transactions, vol. 32, no. 1, pp. 144-146, 2004.
173. R. L. Woltjer, W. Nghiem, I. Maezawa, et al., "Role of glutathione in intracellular amyloid-β precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity, " Journal of Neurochemistry, vol. 93, no. 4, pp. 1047-1056, 2005.
174. B. Liu and Y. A. Hannun, "Inhibition of the neutralmagnesiumdependent sphingomyelinase by glutathione, " The Journal of Biological Chemistry, vol. 272, no. 26, pp. 16281-16287, 1997.
175. D. Allan Butterfield, A. Castegna, C. M. Lauderback, and J. Drake, "Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimers disease brain contribute to neuronal death, " Neurobiology of Aging, vol. 23, no. 5, pp. 655-664, 2002.
176. T. J. Montine, W. R. Markesbery, W. Zackert, S. C. Sanchez, L. J. Roberts II, and J. D. Morrow, "The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimers disease patients, " The American Journal of Pathology, vol. 155, no. 3, pp. 863-868, 1999.
177. J. N. Keller, Z. Pang, J. W. Geddes, et al., "Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid β-peptide: role of the lipid peroxidation product 4-hydroxynonenal, " Journal of Neurochemistry, vol. 69, no. 1, pp. 273-284, 1997.
178. K. S. Montine, P. J. Kim, S. J. Olson, W. R. Markesbery, and T. J. Montine, "4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease, " Journal of Neuropathology and Experimental Neurology, vol. 56, no. 8, pp. 866-871, 1997.
179. S. Patil, L. Sheng, A. Masserang, and C. Chan, "Palmitic acidtreated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons, "Neuroscience Letters, vol. 406, no. 1-2, pp. 55-59, 2006.
180. S. Patil, J. Melrose, and C. Chan, "Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons, "The European Journal ofNeuroscience, vol. 26, no. 8, pp. 2131-2141, 2007.
181. H. Geekiyanage, A. Upadhye, and C. Chan, "Inhibitionof serine palmitoyltransferase reducesAβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimers disease, " Neurobiology of Aging, vol. 34, no. 8, pp. 2037-2051, 2013.
182. L. Liu, R. Martin, and C. Chan, "Palmitate-activated astrocytes via serine palmitoyl transferase increase BACE1 in primary neurons by sphingomyelinases, " Neurobiology of Aging, vol. 34, no. 2, pp. 540-550, 2013.
183. T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, and M. G. Tansey, "Does neuroinflammation fan the flame in neurodegenerative diseases?" Molecular Neurodegeneration, vol. 4, article 47, 2009.
184. L. Liu and C. Chan, "The role of inflammasome in Alzheimers disease, " Ageing Research Reviews, vol. 15, no. 1, pp. 6-15, 2014.
185. M. Jana, C. A. Palencia, and K. Pahan, "Fibrillar amyloid-β peptides activate microglia via TLR2: implications for Alzheimers disease, " The Journal of Immunology, vol. 181, no. 10, pp. 7254-7262, 2008.
186. S. Adam-Klages, D. Adam, K. Wiegmann, et al., "FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase, " Cell, vol. 86, no. 6, pp. 937-947, 1996.
187. A. A. Farooqui, W. Y. Ong, and L. A. Horrocks, "Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders, " Pharmacological Reviews, vol. 58, no. 3, pp. 591-620, 2006.
188. G. Chakraborty, S. Ziemba, A. Drivas, and R. W. Ledeen, "Myelin contains neutral sphingomyelinase activity that is stimulated by tumor necrosis factor-β, " Journal of Neuroscience Research, vol. 50, no. 3, pp. 466-476, 1997.
189. M. A. Sortino, F. Condorelli, C. Vancheri, and P. L. Canonico, "Tumor necrosis factor-β induces apoptosis in immortalized hypothalamic neurons: involvement of ceramide-generating pathways, " Endocrinology, vol. 140, no. 10, pp. 4841-4849, 1999.
190. C. Zeng, J. T. Lee, H. Chen, S. Chen, C. Y. Hsu, and J. Xu, "Amyloid-β peptide enhances tumor necrosis factor-β-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes, " Journal of Neurochemistry, vol. 94, no. 3, pp. 703-712, 2005.
191. S.-D. Chen, J.-H. Yin, C.-S. Hwang, C.-M. Tang, and D.-I. Yang, "Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimers disease and cerebral ischemia, " Free Radical Research, vol. 46, no. 8, pp. 940-950, 2012.
192. Y. Choi, H.-S. Kim, K. Y. Shin, et al., "Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimers diseasemodels, "Neuropsychopharmacology, vol. 32, no. 11, pp. 2393-2404, 2007.
193. R. T. Dobrowsky, C. Kamibayashi, M. C. Mumby, and Y. A. Hannun, "Ceramide activates heterotrimeric protein phosphatase 2A, " The Journal of Biological Chemistry, vol. 268, no. 21, pp. 15523-15530, 1993.
194. C. E. Chalfant, K. Kishikawal, M. C. Mumby, C. Kamibayashi, A. Bielawska, and Y. A. Hannun, "Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid, " The Journal of Biological Chemistry, vol. 274, no. 29, pp. 20313-20317, 1999.
195. A. Mukhopadhyay, S. A. Saddoughi, P. Song, et al., "Direct interaction between the inhibitor 2 and ceramide via sphingolipidprotein binding is involved in the regulation of protein phosphatase 2A activity and signaling, " The FASEB Journal, vol. 23, no. 3, pp. 751-763, 2009.
196. M. Voronkov, S. P. Braithwaite, and J. B. Stock, "Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimers disease, " Future Medicinal Chemistry, vol. 3, no. 7, pp. 821-833, 2011.
197. C. L. Chen, C. F. Lin, C. W. Chiang, M. S. Jan, and Y. S. Lin, "Lithium inhibits ceramide-and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis, " Molecular Pharmacology, vol. 70, no. 2, pp. 510-517, 2006.